Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

por Mendzelevski, Boaz, Ferber, Georg, Janku, Filip, Li, Bob T., Sullivan, Ryan J., Welsch, Dean, Chi, Wei, Jackson, Jeanne, Weng, Onglee, Sager, Philip T.
Publicado 2018

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

por Janku, Filip, Beom, Seung-Hoon, Moon, Yong Wha, Kim, Tae Won, Shin, Young G., Yim, Dong-Seok, Kim, Gun Min, Kim, Hyo Song, Kim, Sun Young, Cheong, Jae-Ho, Lee, Young Woo, Geiger, Barb, Yoo, Sanghee, Thurston, Archie, Welsch, Dean, Rudoltz, Marc S., Rha, Sun Young
Publicado 2022